Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
9.37
+0.06 (0.64%)
At close: Nov 13, 2026, 4:00 PM EST
9.50
+0.13 (1.39%)
After-hours: Nov 13, 2026, 7:30 PM EST
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Monte Rosa Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $25.38. The average 1-year stock price forecast is 170.86% higher than the current stock price, while the lowest is $15 (+60.09%) and the highest is $37 (+294.88%).
Price Target: $25.38 (+170.86%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 8 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $37 | Buy | Reiterates | $37 | +294.88% | Nov 10, 2026 |
| Wedbush | Wedbush | Buy Reiterates $27 | Buy | Reiterates | $27 | +188.15% | Nov 6, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $27 → $25 | Buy | Reiterates | $27 → $25 | +166.81% | Nov 6, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $28 | Buy | Maintains | $28 | +198.83% | Nov 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +166.81% | Nov 6, 2026 |
Financial Forecast
Revenue This Year
91.79M
from 123.67M
Decreased by -25.78%
Revenue Next Year
34.15M
from 91.79M
Decreased by -62.79%
EPS This Year
-1.11
from -0.46
EPS Next Year
-2.08
from -1.11
EPS and Forward PE are based on non-GAAP adjusted numbers.